Details
Stereochemistry | ACHIRAL |
Molecular Formula | 2C2H3O2.Ni.4H2O |
Molecular Weight | 248.8426 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.O.O.O.[Ni++].CC([O-])=O.CC([O-])=O
InChI
InChIKey=OINIXPNQKAZCRL-UHFFFAOYSA-L
InChI=1S/2C2H4O2.Ni.4H2O/c2*1-2(3)4;;;;;/h2*1H3,(H,3,4);;4*1H2/q;;+2;;;;/p-2
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2323003
epithelial tumors in rats: Soluble nickel(II) ion, given to male F344/NCr rats as a single i.p. injection of nickel(II) acetate tetrahydrate at a dose of 90 mumols/kg body weight at 5 weeks of age, proved an effective initiator of renal cortical epithelial tumors
Route of Administration:
Intraperitoneal
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11802473
Human stratum corneum (SC) was prepared by trypsinization of dermatomed cadaver leg skin. The diffusion system included diffusion cells with a spiral line. Aqueous solutions of nickel salts (Ni(NO3)2, NiSO4, NiCl2 and Ni(-OOCCH3)2 at 1% Ni2+ concentration) were used as the donor solution (400 microL/cell). The receptor fluid, pure water, was collected up to 96 h after application of the donor solutions. Nickel concentrations in the donor and receptor fluid, as well as in the SC, were analysed using inductively coupled plasma mass spectrometry (ICP-MS) with a confidence limit of 0.5 ppb. Based on the total recovery of nickel from the experiments, about 98% of the dose remained in the donor solution, whereas 1% or less was retained in SC and less than 1% was found in the receptor fluid. Following an early surge, nickel permeates slowly across SC. The steady-state permeability coefficients of nickel were calculated from the flux data (approximately 5.2-8.5 x 10(-7) cm/h) with no significant difference among the salts. The results concur in principle with earlier studies conducted using the full-thickness human skin in vitro, and suggest that in vivo nickel ions may permeate simultaneously by routes of diffusion such as the shunt pathway, apart from slow transcellular/intercellular diffusion alone.
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
62601
Created by
admin on Sat Dec 16 03:10:15 GMT 2023 , Edited by admin on Sat Dec 16 03:10:15 GMT 2023
|
PRIMARY | |||
|
DTXSID9075458
Created by
admin on Sat Dec 16 03:10:15 GMT 2023 , Edited by admin on Sat Dec 16 03:10:15 GMT 2023
|
PRIMARY | |||
|
6018-89-9
Created by
admin on Sat Dec 16 03:10:15 GMT 2023 , Edited by admin on Sat Dec 16 03:10:15 GMT 2023
|
PRIMARY | |||
|
6SOA8L0560
Created by
admin on Sat Dec 16 03:10:15 GMT 2023 , Edited by admin on Sat Dec 16 03:10:15 GMT 2023
|
PRIMARY | |||
|
1313175
Created by
admin on Sat Dec 16 03:10:15 GMT 2023 , Edited by admin on Sat Dec 16 03:10:15 GMT 2023
|
PRIMARY | RxNorm |
SUBSTANCE RECORD